Progen's distribution arm picks up new agencies
Wednesday, 03 April, 2002
Brisbane-based biotech Progen Industries has been appointed exclusive Australian distributor for two product ranges used by lab researchers.
Progen will distribute Pierce and Endogen brands through its life sciences division, which distributes biological and chemical research products in Australia and New Zealand.
The agreeement should help finance the main thrust of Progen's business which is centered around R&D activity related to its lead anti-cancer drug candidate PI-88 now in clinical trials.
Progen's life sciences division forms part of its commercial services unit, which last financial year generated more than $2.4 million and has already posted a 46 per cent rise in revenues this year. The unit also contract-manufactures potential therapeutics and vaccines under Good Manufacturing Standards (GMP).
Pierce products are used by researchers in protein chemistry, immunology and molecular biology. Endogen is a major supplier of compounds related to the measurement of cytokines and chemokines (the chemical messengers of the immune system).
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
